| Literature DB >> 11116197 |
.
Abstract
An arsenic compound, previously used as an insecticide, is set to become the latest addition to the armoury for treating a rare form of leukaemia. On 26 September 2000, the FDA announced the approval of Trisenox (arsenic trioxide) for the treatment of acute promyelocytic leukaemia (APL), which affects approximately 2000 people each year in the USA.Entities:
Year: 2000 PMID： 11116197 DOI： 10.1016/s1461-5347(00)00318-7
Source DB: PubMed Journal: Pharm Sci Technolo Today ISSN： 1461-5347